Clinical Trials - October 20, 2025
Aqilion announces new clinical pharmacokinetic study results
The company has announced positive results from the ARIA-2 clinical study.
Clinical Trials - October 10, 2025
Herantis announces positive data for HER-096 in Phase 1b trial
Herantis Pharma has announced positive topline results from its Phase 1b trial of HER-096 in people living with Parkinson’s disease, with all primary and secondary endpoints met.
Clinical Trials - October 8, 2025
PharmNovo secures CTA approval in Spain
The company's clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been approved in Spain.
Clinical Trials - October 1, 2025
Gesynta Pharma receives UK approval for a Phase 2 trial
The company's clinical trial application for the company’s Phase 2 trial of vipoglanstat for the treatment of endometriosis has been approved by the UK authorities.
Clinical Trials - September 25, 2025
Hansa Biopharma’s imlifidase meets primary endpoint in Phase 3 trial
The company has announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) adult kidney transplant patients with positive crossmatch against a deceased donor, versus the control arm.
Clinical Trials - September 24, 2025
New study aims to provide more cancer patients with targeted treatment
The new, national study uses genetic analysis of tumors to match cancer patients with targeted drugs – even when these are not yet approved for their specific diagnosis.
